HMGB1 and cholesteatoma: Based on our previous and current results from ex vivo and in vitro studies [12,24,25,26], we hypothesize that the increased level of HMGB1 in sEVs in patients with acquired cholesteatoma may be a new and key factor involved in disease progression.